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Abstract 
Over the past 20 years a number of simulations or models have been developed as a basis for tracking and evaluating the impact of 
pharmacological and other interventions in type 1 and type 2 diabetes mellitus. These models have typically tracked the natural 
course of these diseases generating long-term composite claims for cost-effectiveness. These claims can extend over the lifetime of 
the modeled patient cohort. Set against the standards of normal science, however, these claims lack credibility. The claims presented 
are all too often either immune to failure or are presented in a form that is non-testable. As such they fail to meet the key 
experimental requirements of falsification and replication. Unfortunately, there is a continuing belief that long-term or lifetime 
models are essential to decision-making. This is misplaced. The purpose of this review is to argue that there is a pressing need to 
reconsider the needs of health system decision makers and focus on modeled or simulated claims that are meaningful, testable, 
reportable and replicable in evaluating interventions in diabetes mellitus.  
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Introduction 
Over the past 20 years, considerable time and effort has been 
put into building simulation models to support the evaluation 
of competing interventions in type 1 and type 2 diabetes 
mellitus. These simulations are seen as critical inputs to 
informing health care decision makers for disease states 
which have a significant long-term, if not lifetime, impact on 
both patients and health care payers. The IMS CORE diabetes 
model, for example, has been ‘used extensively to evaluate 
the cost-effectiveness of new therapies … and to inform 
reimbursement decisions, public health issues, resource 
planning, clinical trial design, and optimal patient strategies’1  
 
The purpose of this review is to argue that the faith placed by 
decision makers in, and their apparent acceptance of claims 
made by these various models are misplaced. Rather  than 
these models being seen as a robust and credible framework 
for evaluating the merits of competing products, notably in 
the claims made for the cost-effectiveness of new therapies, 
the models may, to an unknown extent, be misleading. This 
follows from the apparent disregard for the standards of 
normal science; specifically, the ability of these models to 
generate testable predictions to support falsification and 
replication 2.   
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Credibility and the Standards of Normal Science 
The requirement for testable hypotheses in product and 
device impacts is unexceptional. Since the 17th century it has 
been accepted that if a research agenda is to advance, if 
there is to be an accretion of knowledge and if models are to 
generate meaningful hypotheses, then these hypotheses 
must be empirically evaluated. This argument has been well 
documented by Wootton in his recent reassessment of the 
use of language in the idea of the scientific revolution in The 
Invention of Science3 . If a model fails to generate testable or 
measurable hypotheses, then it should be seen as simply a 
construct to support the exploration of imaginary worlds or 
thought experiments and not part of a meaningful research 
program; a program that underpins the notion of progress in 
the accumulation of knowledge. A process described in a 
recent issue of Science as one where ‘The deepest trust in 
scientific knowledge comes from the ability to replicate 
empirical findings directly and independently, whether 
through reanalyzing original data or by creating new data’ 4. 
Unfortunately, in both the natural and social sciences 
replication is rarely carried out. Where attempts to replicate 
clinical claims have been undertaken, for example in 
psychology, false positives seem to be the norm in over 60% 
of replicated studies 5.  
 
The key question is whether or not published simulated or 
modeled claims for comparative cost-effectiveness are 
credible? If claims are testable in a timeframe and for a target 
population that creates a meaningful and evidence-based 
feedback to a formulary committee, then the model meets 
the standards expected in normal science. It is not a question 
of the sophistication of the model. A further issue is whether 
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or not modeled claims can be replicated. As Popper notes, 
‘non-reproducible single occurrences are of no significance to 
science’3 . If they can be reproduced, they contribute to the 
discovery of new facts, establishing the credibility of the 
claims made cumulatively. The issue is one of demarcation. 
Are we to regard models and simulations as science or 
pseudoscience? Are they designed to discover new facts or to 
generate constructed evidence? If models and simulations 
are not designed to support credible and empirically 
evaluable theories and hypotheses then they are best seen as 
pseudoscience in their construction of imaginary worlds 6.  
 
Standards for Cost-Effectiveness Modeling in Diabetes 
A recent review by Henriksson et al. is important because it 
points to a lack of appreciation of the need to apply the 
standards of normal science to simulations or modeled claims 
in diabetes7. The purpose of their review was to evaluate the 
capabilities of diabetes models. In this case in respect of type 
1 diabetes although many of the models could equally 
accommodate type 2 diabetes simulations. Model capabilities 
were assessed in term of the application of ISPOR modelling 
standards 8 9 .  
 
The Henriksson review identified 13 simulations or models in 
type 1 diabetes. Ten of these models were Markov-based, 
two used discrete event simulation and one was the 
Archimedes object-orientated mathematical model. The cycle 
lengths for the Markov and discrete event simulation (with 
one exception) were annual with time horizons ranging from 
8 years to a lifetime. Four of the models were flexible to a 
lifetime simulation, one model only considered a lifetime 
horizon, with the timeframes for the other models ranging 
from 8 years to 100 years (8, 10, 20, 33, 36, 40, 100 years). 
The most common outcomes were: direct costs, life years, 
quality-adjusted life years, incremental cost effectiveness 
ratios and cumulative incidence of complications. Nine of the 
models had apparently gone through some form of 
validation, to include external validation, internal validation 
and cross validation. Details on the form of validation were 
sparse with the authors mentioning only the CARDS trial at 
the Fourth Mount Hood Challenge, which simulated 9-year 
microalbuminuria, retinopathy, and neuropathy outcomes.  
 
Following ISPOR good practice standards, Henriksson et al 
identified a range of key attributes for best practice in type 1 
diabetes models. These attributes included the type of 
simulation, the treatment of uncertainty, choice of maximum 
time horizon, the inclusion of microvascular and 
macrovascular  health states, adverse events, costs and 
QALYs. As far as the time horizon the model wqs concerned 
the authors maintained that “Theoretically, a lifetime horizon 
should be supported in models of chronic and progressive 
diseases like T1DM; however any model with a maximum 
time horizon of ≥ 30 years is likely sufficient in practice”. The 
authors see quality adjusted life years (QALY s) as the gold 
standard as  they “facilitate comparisons across interventions 
…. and are the most important measure of benefit for many 
new interventions”.  
 
The issue of testable claims does not arise; standards for 
falsification and replication are not an issue. The focus is on 
inputs and the ability of the simulation or model to replicate 
the natural course of a chronic disease state. There seems to 
be no consideration of the evidentiary standards that a payer 
might demand when claims for formulary listing are 
presented as discounted cost-per-QALYs over a 30-year time 
horizon. A timeframe that ensures claims are immune to 
falsification.  
 
This lack of consideration of the possibility of meeting the 
standards of normal science and developing models that 
generate testable claims also characterizes two earlier 
reviews of models in type 2 diabetes 10 11  . Both reviews see 
modeled claims extending over amid- to long-term horizon as 
appropriate to meeting the information needs of decision 
makers. The question of the credibility of a claim and the 
possibility of falsification and replication are, again, not an 
issue.  
 
It is worth pointing out, however, that in the more 
comprehensive of the two reviews, Tarride et al., where 17 
type1 and type 2 models were considered a number of 
limitations in respect of the RCTs used to populate the 
models were noted. These included the model structure and 
assumptions, the generalizability of RCT results, possible 
changes in treatment patterns since RCT trials were initiated 
and the generalization of models across treatment settings 
and countries. The authors’ response, rather than any 
reference to the standards of normal science, is to suggest, 
given the number of models and their inherent variability, 
that a reference case to capture clinical and utility data 
should be developed for all new models. This has not 
occurred. 
 
Discussion  
The recommendation by Tarride et al for a reference 
standard raises the question of the justification for simulated 
claims. Does the fact that long-term or lifetime simulated 
claims can be published, even though they are immune to 
failure, point to an acceptance of what may be described as a 
relativist position where no body of evidence is superior to 
another? Is the success of a research program focused on 
constructing and comparing type 1 and type 2 diabetes 
simulations reflective of a consensus opinion that in models 
or simulations evidence is never discovered, merely 
constructed? Instead of coming to grips with reality and 
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applying the standards of normal science to the discovery of 
new facts through experimentation, is the reality of science 
about rhetoric, persuasion and authority?        
 
More to the point: can simulations fail? Or, in the argument 
for a reference or benchmark simulation, are we attempting 
to capture the critical or similar features of a ‘diabetic’ 
reality? Are we being asked to subscribe to a belief that if the 
simulated input conditions and the simulated core 
mechanism of the diabetes model correspond to reality, the 
sufficient condition character of the simulation assures us 
that the output is necessarily entailed and predictions for the 
target diabetes population must correspond to reality? 
The point surely is that simulations can fail. They can fail in 
their correspondence to input conditions, to the core 
mechanism and to their predictions. Indeed, the lack of 
correspondence and multiple failures to meet benchmarks 
set by randomized clinical trials have been amply 
demonstrated in the Mount Hood challenges12 13  . Indeed, it 
is always possible to reverse engineer a simulation to 
generate a required outcome! If we accept that simulations 
can fail, then it seems paradoxical that we persist in 
publishing and comparing simulated output claims that are 
immune to falsification. Or, if the claims are within a 
timeframe that is open to empirical evaluation, failing to 
provide evidence that the claims meet the standards of 
normal science. It seems pointless to ask for a reference case 
model if, as in the case of the reference case required by the 
National Institute for Health and Care Excellence, it merely 
entrenches modeled or simulated claims that are immune to 
failure14 .   
 
As a case study, consider a recent validation of the IMS Core 
diabetes model. Although the authors recognize the potential 
role and power of predictive validation, this is put to one side 
on the grounds that the time frame for completing their 
analysis preludes this approach. Putting predictive validation 
to one side, as noted above, is to put to one side the 
standards of normal science. There is no consideration given 
to ability of the IMS CORE model to generate testable claims 
in target populations; of the need to distinguish claims that a 
potentially evaluable from those that, in the time frame of 
the simulation, are immune to failure. 
 
Conclusions 
To the extent that the supporters of simulated diabetes 
models believe that the model can be defended on the 
grounds that it ‘reflects reality’, or is a ‘reasonable 
representation’ of what is ‘out  there’ (whatever those terms 
actually mean), it is worth reflecting on Popper’s statement 
that ‘never in science are inferences drawn from mere 
observational experience to the prediction of future 
events’ 15. Or, to put it in more practical terms: not all swans 
are white. Reporting simulated model results for 30 and 40 
year time frames is clearly a challenge to credibility, if not 
credulity. Attempting to justify a model’s credibility on the 
‘realism’ of its assumptions is not acceptable.  
 
If simulations or models in type 1 and type 2 diabetes are to 
be seen as credible, then there needs to be a commitment to 
move away from generating claims that are immune to failure 
and to focus instead on developing claims that can be 
empirically evaluated. This does not mean competition 
between models to assess their correspondence to 
benchmarks, but to develop claims that can be independently 
assessed in target diabetes populations.  
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